Comparison Of Early-Stage High-Grade Serous Primary Fallopian Tube Cancers and Epithelial Ovarian Cancers: A Multicenter Study

• Published in: Oncology research and treatment Vol. 40; no. 4; p. 203
• Main Authors: Gungorduk, Kemal, Ozdemir, Aykut, Selcuk, Ilker, Telli, Elcin, Şahin, Öztürk, Toptaş, Tayfun, Akman, Levent, Güzel, Ahmet B, Taşkın, Salih, Öge, Tufan, Güngördük, Özgü, Gokçü, Mehmet, Gungor, Tayfun, Yaşar, Levent, Terek, Mustafa C, Ozan, Hakan, Ozsaran, Aydın, Sancı, Muzaffer, Vardar, Mehmet A, Meydanlı, Mehmet M, Yalçın, Ömer T, Ortac, Fırat, Özalp, Sinan
• Format: Journal Article
• Language: English
• Published: Netherlands 2017
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant - mortality; Chemotherapy, Adjuvant - statistics & numerical data; Diagnosis, Differential; Disease-Free Survival; Early Detection of Cancer; Fallopian Tube Neoplasms - drug therapy; Fallopian Tube Neoplasms - mortality; Fallopian Tube Neoplasms - pathology; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - mortality; Neoplasms, Glandular and Epithelial - pathology; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Prevalence; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Turkey; Turkey
• ISSN: 2296-5262
• DOI: 10.1159/000458440

We compared the disease free-survival (DFS) and overall survival (OS) rates of patients with high-grade serous primary fallopian tube cancer (HG-sPFTC) and high-grade serous epithelial ovarian cancer (HG-sEOC).
22 early-stage cancer patients (International Federation of Gynecology and Obstetrics (FIGO) stages I-II) with HG-sPFTC were retrospectively evaluated. In addition, 44 control patients diagnosed with HG-sEOC were matched to these patients with respect to tumor stage at diagnosis. All patients underwent complete surgical staging, followed by adjuvant chemotherapy. Kaplan-Meier curves were used to generate survival data.
The mean age of HG-sPFTC patients was 59.4 ± 6.2 years, and that of HG-sEOC patients 55.2 ± 11.0 years (p = 0.002). All patients underwent 6 cycles of platinum-based adjuvant chemotherapy. All operations were optimal. The 5-year DFSs were 77.3% for HG-sPFTC patients and 75% for HG-sEOC patients (p = 1.00).The 5-year OS rates were 81.8% in women with HG-sPFTC and 77.3% in those with HG-sEOC (p = 0.75).
The DFS and OS rates of patients with early-stage (FIGO stages I and II) HG-sPFTC and HG-sEOC were similar. The surgical and adjuvant therapy management of these malignancies should be similar.